Introduction: In order to explore the mechanism of action of valproate (VPA) in idiopathic generalized epilepsy (IGE), the effect of VPA on cortical EEG activity was investigated. Hypothesis: VPA decreases EEG synchronization in the delta and theta frequency bands in a use-dependent manner in IGE patients. Methods: First setting: EEG records of 17 untreated IGE patients (NAE group) were analyzed and compared to those of 15 healthy controls (NC group). Second setting: EEG recorded in the untreated condition (NAE) was compared to the EEG recorded in the treated condition (VPA) of the patient group. Technique and analysis: 2 min of eyesclosed, waking EEG background activity (without epileptiform potentials and artifacts) were analyzed. Absolute power (AP) and mean frequency (MF) were computed for 19 electrodes and four frequency bands (d = 1.5-3.5 Hz, u = 3.5-7.5 Hz, a = 7.5-12.5 Hz, b = 12.5-25.0 Hz). Log-transformed data entered further analysis. Group differences were computed by means of parametric statistics including correction for multiple comparisons. The VPA-related changes (APvpa À APnae) were correlated with the degree of the baseline abnormality (APnae) and the daily dose/serum levels of VPA. Main results: Statistically significant ( p < 0.05, corrected) changes in the first setting: diffuse delta, theta, alpha AP increase, mainly right hemispheric beta AP increase was found in the NAE group, as compared to the NC group. Second setting: VPA decreased delta and theta AP. Strong correlation was demonstrated between the degree of the initial AP abnormality and the VPA-related AP decrease. AP decrease did not correlate with the daily dose and the serum level of the drug. Conclusion: The hypothesis that VPA decreased EEG synchronization in the delta and theta frequency bands in a use-dependent manner was supported. The findings contribute to the understanding of the action of VPA at the network level.
Introduction
Valproate (VPA) is a widely used antiepileptic drug that is effective in most epilepsy syndromes. The efficacy of VPA against focal seizures is well explained by its Na + channel blocking property and the consecutive decrease of repetitive neuronal firing. 1 On the other hand, the mechanism of action of VPA against absences and myoclonic seizures remains enigmatic. The electrographic patterns of the latter seizures are generalized, bilaterally synchronous spike-wave (GSW) paroxysms. The Na + channel blocking property of VPA cannot explain its efficacy against GSW-type seizures. Chiefly Na + channel blocker drugs like carbamazepine and phenytoin do not control these seizures in the experimental setting 2 and in humans. Instead, they frequently aggravate absences and myoclonia in patients with idiopathic generalized epilepsy, IGE. 3 Decreasing the thalamic T-Ca 2+ currents was suggested as the mechanism of the antiabsence effect of VPA. Actually, this effect was demonstrated in peripheral ganglion neurons of the rat, 4 but was not found in thalamic neurons. 5 The latter finding is hardly compatible with the T-Ca 2+ theory of the antiabsence effect of VPA. Albeit some further theories were created in the past two decades, the state of art is that none of the established subcellular and molecular effects of VPA explains its efficacy against GSW-type seizures. 6 A likely cause of this uncertainty is that drug actions established in neuronal preparations cannot always explain changes at the network level. 7 In harmony with this statement, neuroscientists recommended the investigation of intact brains as the preferable approach to ''global brain functions and . . . paroxysmal activities''. 8 There is no doubt that generalized seizures and their modification or abolition belong to this category of events. Thus, assessing the effect of VPA on network-generated electromagnetic brain activity might be an alternative approach to explore the effect of the drug on the central nervous system. The core element of IGE pathophysiology is abnormally synchronized bioelectric activity across a wide frequency range (see below) in thalamo-cortical and cortico-cortical networks. [9] [10] [11] As to avoid confusion, hereunder the term ''synchronization'' refers to simultaneous activation of great synaptic masses in the cortex as recorded at a large spatial scale. 12 Most striking expressions of increased synchronization are the 2.5-6 Hz ictal and interictal GSW paroxysms in the EEG records of IGE patients. However, spectral analysis revealed that increased synchronization in the 0.5-100 Hz frequency range is permanently present in the interictal state, too. This means that it was demonstrated in epochs of interictal background activity without GSW paroxysms. [13] [14] [15] In a preliminary study we demonstrated that decreased seizure propensity was accompanied by decreased EEG synchronization in the delta and theta frequency bands in IGE patients. 16 However, the methods used in that study did not allow the detailed description of the drug-related changes. The aim of the present study was to investigate the effect of chronic VPA treatment on EEG synchronization in the 1.5-25 Hz frequency range at the network level. In particular, we tested the hypothesis that VPA decreases pathological synchronization in the delta and theta bands in a use-dependent manner in IGE patients. Use-dependent action is a principle in pharmacology indicating that the magnitude of the drug effect is proportional to the degree of the baseline pathophysiological abnormality. While the use-dependent dynamics of the Na + channel blocking effect of VPA is well-known, 1 the dynamics of the VPA effect at the network level has not been investigated yet. Our hypothesis was built on the above listed pieces of evidence with special reference to the VPA-related EEG normalization of background activity, 16, 17 and, by analogy, the usedependent action of another antiabsence drug, lamotrigine, on EEG synchronization in IGE patients. 18 
Patients and methods
The study design was approved by the Local Research Ethics Committee of Kenézy Gyula Hospital. The patients were diagnosed and treated as usual. No diagnostic procedure or treatment was indicated, missed, or postponed for study purposes. Inclusion criteria were: unmedicated IGE patients, who were referred to the Epilepsy Center and fulfilled the diagnostic criteria for ''IGE with variable phenotypes '' 19 ; age of onset after the eighth year of age; the presence of absences and/or myoclonic seizures. Exclusion criteria were: any medication except oral contraceptives, alcohol or drug abuse; any medical condition that is known to influence EEG activity; generalized tonic-clonic seizure in the 5 days before EEG investigation. Neurological and EEG investigations were done at the first visit. VPA monotherapy started the next day with an 500 mg evening dose of the same, controlled release product. In addition, regular sleep and life style was recommended. If the seizures persisted the daily dose was progressively increased until seizure control was reached. The patients recorded the date of seizures and the adverse events in their seizure diary. The second EEG was done 3 months after the first EEG, because initial, transient EEG effects of the drug disappear by the 90th day of treatment. 20 By this time all the patients (11 females, 6 males; age limits: 16 and 31 years average: 19.4 years) were seizure-free, and no patient experienced symptoms or complaints indicating adverse effects of the drug. The daily dose of VPA was in the 500-1500 mg range, serum levels (determined in the morning, just before of the second EEG investigation) were within the therapeutic range. The normal control group (NC) was composed of 15 healthy persons (10 females, 5 males, age limits: 16 and 32 years, average: 21.9 years). The age difference between the two groups was statistically not significant (unpaired t-test, p > 0.05). The EEG data of the NC group were used as normative reference, facilitating the proper interpretation of the drug-related changes on the normality-abnormality axis.
EEG recording and data analysis
All recordings were carried out in the morning, after a night of sufficient sleep, in the same semi-isolated room, with the same Brain Quick (Micromed SRL, Mogliano Veneto, Italy) digital equipment, by trained personnel, according to recommended standards for quantitative EEG studies. 21 Silver-silver chloride electrodes were placed according to the 10-20 system, fixed by appropriate adhesive and conductive gel. Impedances did not exceed 5 kV. Nineteen-channel EEG was recorded against linked ears reference. Additional bipolar derivations were used to differentiate between EEG and eye movements potentials, and to detect EMG activity. In the EEG derivations the filters were set at 0.1 and 30 Hz. Sampling frequency was 128 s À1 . Twelve-bit on-line digitization was used. Thirty minutes EEG was recorded in waking-relaxed, eyes-closed condition. The first 2 min of artifact-free editable EEG activity (sixty 2-s epochs) were selected for quantitative EEG analysis. Our standard epoch selection protocol includes: (1) the presence of continuous physiological waking alpha activity with alpha voltage maximum in posterior regions, (2) the absence of artifacts, epileptiform potentials, and other nonstationary elements, and (3) the absence of patterns indicating drowsiness or arousal. Epoch selection was done blindly, without knowing the person's name and condition.
After final visual revision of the edited epochs they were processed by the Neurometric Analysis system software, Version 2.80. Fast Fourier transformderived data were used to compute absolute power (AP; microvolts squared) and mean frequency (MF; Hz) for the 19 derivations and four frequency bands (d = 1.5-3.5 Hz, u = 3.5-7.5 Hz, a = 7.5-12.5 Hz, b = 12.5-25.0 Hz). Leakage was reduced by Hanning window. As to approximate Gaussian distribution the raw data were logarithmically transformed. The transformed data entered group analysis. In the first setting the group of untreated patients (NAE) was compared to the normal control group (NC) by t-tests for independent datasets. In the second setting the untreated (NAE) and treated (VPA) conditions of the patients were compared by t-tests for interdependent datasets. The probability of type-I errors inherent to multiple comparisons was reduced by Bonferroni's corrections in both settings. Corrected p < 0.05 differences were accepted as statistically significant. In addition, VPA-related changes of band power (APvpa À APnae) were compared between the averages of the lateral (F7, T3, T5, F8, T4, T6) and the medial (the 3 midline + 10 parasagittal) electrode sites by t-tests for interdependent datasets.
Correlation between the variables was computed by the nonparametric (Spearman) method for mathematical reasons. The relationship between the VPA-related AP changes (APvpa À APnae) and the baseline abnormality (APnae) was evaluated for all bands and electrodes. Also the correlation between the VPA-related AP changes and the daily dose and serum levels of VPA was investigated. For the latter correlations p < 0.05 (uncorrected) values were accepted as statistically significant. Tables 1 and 2 show the raw data that reflect the original magnitude AE S.D. of the quantitative EEG variables and are more comfortable to the reader than the log-transformed values. The p-values were derived from the comparison of the log-transformed values.
Results

NAE versus NC comparison
The mean finding was the overall excess of absolute power in the untreated IGE patients (Table 1) . Delta and theta AP were about two to four times higher in the NAE than in the NC group, and the differences were statistically significant ( p < 0.001 in all derivations). Also alpha AP was increased in the NAE group; however, the p-values suggested that the deviation from the normative data (NC) is less marked. Beta AP increase was moderate and asymmetrical.
The range of the MF differences was <0.1 Hz for delta; <0.2 Hz for theta; <0.5 Hz for alpha; <0.2 Hz for beta. Thus, MF differences were small and statistically not significant in most (72/76) cases. 
NAE versus VPA comparison
The main result of this comparison was the overall decrease of AP in the treated condition as compared to the untreated one (Table 2) . AP values in the treated patients took intermediate positions between the NC and NAE results. Delta AP differences were statistically significant in all derivations over the right hemisphere but only in two derivations over the left one. Theta AP differences were statistically significant at all electrode sites, except two, left hemispheric derivations. Comparing the pvalues at the mirror electrode sites suggested that the right hemispheric theta differences are more marked than their left hemispheric counterparts. Alpha and beta AP decreased in all derivations but the differences were statistically not significant except for alpha AP in a single derivation. The VPA-related decrease of power was more marked in the medial than in the lateral derivations. However, medial-lateral differences were statistically significant only for the delta ( p = 0.0019) and theta ( p = 0.0080) bands.
The correlation coefficients suggested a strong relationship between the decrease of AP (APvpa À APnae) and the degree of the initial abnormality (APnae) in all derivations and frequency bands: the higher the initial APnae value, the greater the VPA-related AP decrease (Table 3 ). An illustrative example is given in Fig. 1 . The coefficient of determination, ''r squared'' 22 was in the range of 0.30-0.90, suggesting a considerable biological interrelatedness.
MF changes were small and statistically not significant in all bands and derivations. However, the consistency of the electrode-related changes concerning magnitude and direction of the changes 228 B. Clemens Table 1 (Continued )
Mean frequency .61 9.63 9.59 9.60 9.58 9.58 9.72 9.75 9.92 9.95 9.63 9.64 9.65 9.65 9.79 9.79 9.59 9.54 9.71 9.68 (decrease in theta MF, increase in alpha and beta MF) should be noted.
Other results
Correlation coefficients between the daily doses of VPA and AP decrease (r = 0.23, p > 0.05), and between serum levels of VPA and AP decrease (r = 0.19, p > 0.05) indicated that the AP-decreasing effect of VPA is neither dose-dependent nor serum level dependent.
Discussion
Despite the efforts of pharmacological research the molecular-subcellular mechanism of action of VPA against GSW-type seizures remains enigmatic. 6 In this study we used an alternative approach and tried to grasp the net effect of VPA on the cerebral cortex, the structure that plays the main role in generating seizures. The scientific rationale of the EEG approach is that IGE and its pathophysiology can be properly characterized in terms of disturbed bioelectric activity. Scalp EEG reflects EEG dynamics at a large spatial scale, allowing the quantitative assessment of network-generated, synchronized activities. 23 Within this framework, AP reflects the degree of synchronization of the cortical EEG sources at a given frequency (or, in a frequency band), and is proportional to the number of the synchronously activated generators that contribute to the signal. 24 MF changes (in particular, the decrease of MF) usually indicate diffuse cortical lesions or metabolic derangement of the cortex and its neuronal interconnections. Thus, VPArelated delta and theta AP changes without significant MF shifts indicate the ''pure'' decrease of synchronization in these frequency bands, without altered tuning of the selectively distributed neuronal networks that are the anatomical basis of the normal EEG rhythms. 25 The use-dependent action of VPA on synchronization
In the NC versus NAE comparison we confirmed that the main bioelectric abnormality of IGE is increased synchronization at the thalamo-cortical level of the brain. 14, 15, 17 The abnormality was particularly marked in the delta and theta bands.
The selective or, preferential effect of VPA on pathological but not normal network activity was first suggested by an evoked potential study. VPA normalized abnormally large-amplitude visual evoked potentials in patients with photosensitive 230 B. Clemens Table 2 (Continued )
Mean frequency epilepsy but did not affect the normal responses of healthy persons. 26 An investigation carried out in IGE patients disclosed the selectivity of the VPA effect in terms of frequency bands: the drug decreased spectral power only in the bands (delta, theta, and, to a lesser degree, alpha) where power had been pathologically increased in the untreated condition. 16 Topographic selectivity was reported in another paper: VPA normalized Omega-complexity (a linear measure of spatial synchrony) only in the anterior part of the cortex where this measure had been pathologically altered in the untreated state. 17 Our present results support the earlier findings and the idea of the selective action of VPA on abnormal EEG activity. First, the quantitative EEG variables that reflect the activity of anatomically and physiologically diverse neuronal mechanisms were influenced disparately. VPA significantly decreased AP that had been pathologically increased in the untreated condition but did not affect MF that had been near normal in the untreated patients. Second, VPA decreased (normalized) synchronization in the delta and theta bands that had been markedly abnormal in the untreated condition but did not significantly decrease synchronization in the alpha and beta bands where the baseline abnormality had been less marked.
A novel finding is that the VPA-related decrease of synchronization was significantly greater in the medial (midline + parasagittal) leads than in the lateral derivations. The possible reason for this difference may be the different thalamic connectivity of the medial and lateral cortical regions as defined above. Roughly, the medial electrodes mainly explore the frontal and parietal cortex where the majority of the so-called non-specific thalamo-cortical fibers terminate, mediating the synchronized recruiting cortical response and the spike-wave paroxysms. 27 The network containing the fronto-parietal cortex, the reticular and relay nuclei of the thalamus and their interconnections is the anatomical substrate of the generalized seizures in the animal models of IGE. 9, 10 Thus, it is not surprising that the effect of VPA was greater in these areas than in the lateral cortex that only receives the minority of the non-specific thalamo-cortical fibers and plays an uncertain but presumably minor (if any) role in the pathophysiology of IGE. The fact that VPA caused significant decrease of delta-theta synchronization also in the lateral derivations might be explained by the increased synchronization in the same frequency range within the anatomically dense cortico-cortical network, the synchronizing role of which has been clearly demonstrated in IGE models. 11 In addition, volume conduction might contribute to the findings in the lateral derivations. 12 An unexpected finding was the right hemispheric preponderance of the VPA-related decrease of delta and theta synchronization. However, the detailed analysis and discussion of hemispheric asymmetry in natural and drug-related conditions is beyond the scope of this study. The above listed results of the NAE versus VPA comparison strongly support the idea that VPA selectively decreases synchronization in the cortical compartment of the networks that are pathologically synchronized ictally and interictally. This overall conclusion was quantitatively refined by our correlation studies. The other novelty of this study is that the relationship between the drug's action and the degree of the baseline abnormality (increased synchronization) was quantitatively established. In other words, the use-dependent action of VPA on EEG synchronization (as postulated in our hypothesis) was demonstrated.
In theory, the daily dose and serum level of VPA might co-determine the quantitative EEG changes. The lack of meaningful correlation between the decrease of synchronization and the pharmacological data (daily dose and serum level of VPA) is in accord with a prior paper reporting no correlation between EEG spectral variables and serum levels of VPA. 28 The obvious shortcoming of this study is the lack of a control group composed of age-and sexmatched healthy persons. However, the exposure of healthy people to an already marketed and not entirely harmless drug (VPA) for study purposes was hardly acceptable for ethical reasons. Pieces of evidence suggest that our results are reliable even in the absence of a control group. The results were robust and statistically highly significant in both settings, and the magnitude of the changes highly exceeded the range of the test-retest variability of the quantitative EEG parameters. 29 The overall and neurological condition of the patients was controlled clinically, and the EEG environment and procedure were always the same. Thus, disregarding the effect of VPA, influences that significantly alter the patients' condition and confound the EEG results in a systemic manner 30 are highly improbable. Small changes in physiological parameters that are by nature random-like cannot be excluded but do not generate statistically highly significant differences. Finally, the reported effect of VPA on EEG synchronization in the 1.5-25 Hz frequency range is not an obligatory reaction of the brain to VPA exposure, because using the same study design (before treatment versus on treatment) we did not observed it in a group of migraine patients who received VPA as prophylactic treatment (Clemens, unpublished results).
The possible clinical relevance to the findings
The search after electrophysiological markers of seizure liability and seizure control has been advocated in an Editorial. 31 From this perspective, the possible clinical significance of our findings may be inherent in the established relationship between EEG synchronization, excitability of the cortex, and seizure liability as discussed in several papers. [32] [33] [34] Within this framework VPA-related decrease of synchronization might be related to the decrease of seizure propensity. In fact, the decrease of EEG synchronization was associated with complete seizure control in our patients. However, EEG normalization should not be interpreted as a marker of good therapeutic response for several reasons. In addition to the synchronization of the cortical neuronal mass, seizure liability and seizure control are modified at subcortical sites, 35 and influenced by genetic factors. 36 The relationship between decreased synchronization and seizure control should be investigated empirically, correlating individual, VPA-related changes with clinical outcome variables in a sufficient number of VPA-responder and nonresponder IGE patients.
